statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.
The post IMMX...

IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 316,600 shares, a...

Immix Biopharma, Inc. (NASDAQ:IMMX) Sees Large Growth in Short Interest

LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) ( ImmixBio , Company , We or Us or IMMX ), a clinical-stage biopharmaceutical company trailblazing...

Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial

Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
 Immix Biopharma Announces Be Proactive in AL AL Amyloidosis Awareness...

Immix Biopharma Announces  Be Proactive in AL  AL Amyloidosis Awareness Initiative

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...

Immix Biopharma 12 Month Review Progress Update

European Orphan Drug Designation ( ODD ) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU...

Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Immix Biopharma 5.5M share  priced at $2.71

LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the Company ), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease...

Immix Biopharma Announces Proposed Public Offering of Common Stock

LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ( Immix Biopharma , Company , We or Us , Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell...

Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

Immix Biopharma (NASDAQ:IMMX  Get Free Report) and Sage Therapeutics (NASDAQ:SAGE  Get Free Report) are both small-cap medical companies, but which is the superior business? We will...

Critical Survey: Immix Biopharma (NASDAQ:IMMX) versus Sage Therapeutics (NASDAQ:SAGE)

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Volume	83,185.00
52-Wk High	$7.75
52-Wk Low	$1.40

IMMX Immix Biopharma Inc

About

Feed

News

Fundamentals